Posted by linkadge on April 1, 2013, at 20:07:36
In reply to Re: Long-term antidepressant studies, posted by linkadge on April 1, 2013, at 19:47:27
Also, most of the new treatments for depression have nothing to do with monoamine reuptake inhibition.
See: http://www.neurotransmitter.net/newdrugs.html
Different antidepressants have different binding profiles. For instance amitriptyline is a potent trk-b agonist, mimicking the effects of brain derived neurotrophic factor. Fluvoxamine is a sigma-1 agonist, mimicking the effects of nerve growth factor NGF.
poster:linkadge
thread:1041418
URL: http://www.dr-bob.org/babble/20130322/msgs/1041512.html